Key Takeaways:
Aardvark Therapeutics (NASDAQ: AARD) shares cratered 56% after the company announced on March 2 a halt to its pivotal Phase 3 trial for its lead drug candidate, ARD-101.
The development and severe market reaction have prompted national shareholder rights firm Hagens Berman to open an investigation into whether Aardvark may have misled investors, the firm announced on April 10.
The stock plummeted $7.02 after the company stopped its Hunger Elimination of Reduction Objective ("HERO") trial. The study was evaluating the efficacy and safety of ARD-101 as a treatment for hyperphagia, or insatiable hunger, in patients with Prader-Willi Syndrome ("PWS").
The halt of a late-stage trial for a lead drug candidate severely jeopardizes a biotech company's future revenue streams. The subsequent investigation by Hagens Berman introduces significant legal and financial risk, likely leading to sustained downward pressure on the stock and potential class-action lawsuits.
The decline marks the stock's lowest point since its public offering, testing investor confidence ahead of any potential legal proceedings. The focus for investors will now shift to the outcome of Hagens Berman's investigation and the possibility of a securities fraud lawsuit.
This article is for informational purposes only and does not constitute investment advice.
